Kiniksa Pharmaceuticals International (KNSA) Accumulated Expenses (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Accumulated Expenses for 10 years, with the latest figure at $14.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 62.17% year-over-year to $14.3 million; the trailing twelve-month figure through Mar 2026 stood at $14.3 million (up 62.17% YoY), and the FY2025 full-year result was $42.0 million, up 29.87% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $14.3 million, down from $42.0 million in the prior quarter.
• The five-year high for Accumulated Expenses was $44.7 million in Q1 2024, with the low at $4.9 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $23.4 million across 5 years, with a median of $20.9 million in 2023.
• Annual changes were most pronounced in 2022 — Accumulated Expenses sank 83.72% — and 2023, when it jumped 376.6%.
• Kiniksa Pharmaceuticals International's Accumulated Expenses stood at $11.2 million in 2022, then surged by 147.28% to $27.7 million in 2023, then grew by 16.69% to $32.4 million in 2024, then climbed by 29.87% to $42.0 million in 2025, then tumbled by 66.04% to $14.3 million in 2026.
• The last three Accumulated Expenses figures came in at $14.3 million (Q1 2026), $42.0 million (Q4 2025), and $17.0 million (Q3 2025), per Business Quant data.